Global Retinal Drugs Market 2025-2029

Description

List of Tables

The retinal drugs market is forecasted to grow by USD 9434.9 mn during 2024-2029, accelerating at a CAGR of 7.1% during the forecast period. The report on the retinal drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rise in prevalence of retinal diseases, emergence of advanced diagnostic tools, and patient assistance programs.

Market Scope
Base Year	2025
End Year	2029
Series Year	2025-2029
Growth Momentum	Accelerate
YOY 2025	6.5%
CAGR	7.1%
Incremental Value	$9434.9 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's retinal drugs market is segmented as below:

By Distribution Channel

Hospital pharmacy
Retail pharmacy
Online pharmacy

By Indication

Macular degeneration
Diabetic eye disease
Others

By Drug Class

VEGF-A antagonist
TNF-A inhibitor

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the development of innovative therapies as one of the prime reasons driving the retinal drugs market growth during the next few years. Also, rise in demand for sustained-release ocular formulations and advances in diagnostic techniques will lead to sizable demand in the market.

The report on the retinal drugs market covers the following areas:

Retinal Drugs Market sizing
Retinal Drugs Market forecast
Retinal Drugs Market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading retinal drugs market vendors that include AbbVie Inc., Alcon Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Johnson and Johnson Services Inc., Kubota Corp., MeiraGTx Holdings Plc., Novartis AG, Ocular Therapeutix Inc, Oxurion N, Pfizer Inc., Regeneron Pharmaceuticals Inc., REGENXBIO Inc, Sanofi SA, Santen Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Visufarma. Also, the retinal drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR70326

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market By Geographical Landscape
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Market Segmentation by Indication
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
2.3 Factors of disruption
- Overview on factors of disruption
2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029

3 Market Landscape

3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
3.2 Market characteristics
- Market characteristics analysis
3.3 Value chain analysis
- Value chain analysis

4 Market Sizing

4.1 Market definition
- Offerings of companies included in the market definition
4.2 Market segment analysis
- Market segments
4.3 Market size 2024
4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ million)
- Data Table on Global - Market size and forecast 2024-2029 ($ million)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)

5 Historic Market Size

5.1 Global Retinal Drugs Market 2019 - 2023
- Historic Market Size - Data Table on Global Retinal Drugs Market 2019 - 2023 ($ million)
5.2 Distribution Channel segment analysis 2019 - 2023
- Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
5.3 Indication segment analysis 2019 - 2023
- Historic Market Size - Indication Segment 2019 - 2023 ($ million)
5.4 Drug Class segment analysis 2019 - 2023
- Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

6.1 The AI impact on global retinal drugs market

7 Five Forces Analysis

7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029

8 Market Segmentation by Distribution Channel

8.1 Market segments
- Chart on Distribution Channel - Market share 2024-2029 (%)
- Data Table on Distribution Channel - Market share 2024-2029 (%)
8.2 Comparison by Distribution Channel
- Chart on Comparison by Distribution Channel
- Data Table on Comparison by Distribution Channel
8.3 Hospital pharmacy - Market size and forecast 2024-2029
- Chart on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
- Data Table on Hospital pharmacy - Market size and forecast 2024-2029 ($ million)
- Chart on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
- Data Table on Hospital pharmacy - Year-over-year growth 2024-2029 (%)
8.4 Retail pharmacy - Market size and forecast 2024-2029
- Chart on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
- Data Table on Retail pharmacy - Market size and forecast 2024-2029 ($ million)
- Chart on Retail pharmacy - Year-over-year growth 2024-2029 (%)
- Data Table on Retail pharmacy - Year-over-year growth 2024-2029 (%)
8.5 Online pharmacy - Market size and forecast 2024-2029
- Chart on Online pharmacy - Market size and forecast 2024-2029 ($ million)
- Data Table on Online pharmacy - Market size and forecast 2024-2029 ($ million)
- Chart on Online pharmacy - Year-over-year growth 2024-2029 (%)
- Data Table on Online pharmacy - Year-over-year growth 2024-2029 (%)
8.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
- Data Table on Market opportunity by Distribution Channel ($ million)

9 Market Segmentation by Indication

9.1 Market segments
- Chart on Indication - Market share 2024-2029 (%)
- Data Table on Indication - Market share 2024-2029 (%)
9.2 Comparison by Indication
- Chart on Comparison by Indication
- Data Table on Comparison by Indication
9.3 Macular degeneration - Market size and forecast 2024-2029
- Chart on Macular degeneration - Market size and forecast 2024-2029 ($ million)
- Data Table on Macular degeneration - Market size and forecast 2024-2029 ($ million)
- Chart on Macular degeneration - Year-over-year growth 2024-2029 (%)
- Data Table on Macular degeneration - Year-over-year growth 2024-2029 (%)
9.4 Diabetic eye disease - Market size and forecast 2024-2029
- Chart on Diabetic eye disease - Market size and forecast 2024-2029 ($ million)
- Data Table on Diabetic eye disease - Market size and forecast 2024-2029 ($ million)
- Chart on Diabetic eye disease - Year-over-year growth 2024-2029 (%)
- Data Table on Diabetic eye disease - Year-over-year growth 2024-2029 (%)
9.5 Others - Market size and forecast 2024-2029
- Chart on Others - Market size and forecast 2024-2029 ($ million)
- Data Table on Others - Market size and forecast 2024-2029 ($ million)
- Chart on Others - Year-over-year growth 2024-2029 (%)
- Data Table on Others - Year-over-year growth 2024-2029 (%)
9.6 Market opportunity by Indication
- Market opportunity by Indication ($ million)
- Data Table on Market opportunity by Indication ($ million)

10 Market Segmentation by Drug Class

10.1 Market segments
- Chart on Drug Class - Market share 2024-2029 (%)
- Data Table on Drug Class - Market share 2024-2029 (%)
10.2 Comparison by Drug Class
- Chart on Comparison by Drug Class
- Data Table on Comparison by Drug Class
10.3 VEGF-A antagonist - Market size and forecast 2024-2029
- Chart on VEGF-A antagonist - Market size and forecast 2024-2029 ($ million)
- Data Table on VEGF-A antagonist - Market size and forecast 2024-2029 ($ million)
- Chart on VEGF-A antagonist - Year-over-year growth 2024-2029 (%)
- Data Table on VEGF-A antagonist - Year-over-year growth 2024-2029 (%)
10.4 TNF-A inhibitor - Market size and forecast 2024-2029
- Chart on TNF-A inhibitor - Market size and forecast 2024-2029 ($ million)
- Data Table on TNF-A inhibitor - Market size and forecast 2024-2029 ($ million)
- Chart on TNF-A inhibitor - Year-over-year growth 2024-2029 (%)
- Data Table on TNF-A inhibitor - Year-over-year growth 2024-2029 (%)
10.5 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
- Data Table on Market opportunity by Drug Class ($ million)

11 Customer Landscape

11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

12.1 Geographic segmentation
- Chart on Market share By Geographical Landscape 2024-2029 (%)
- Data Table on Market share By Geographical Landscape 2024-2029 (%)
12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ million)
- Data Table on North America - Market size and forecast 2024-2029 ($ million)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ million)
- Data Table on Europe - Market size and forecast 2024-2029 ($ million)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ million)
- Data Table on Asia - Market size and forecast 2024-2029 ($ million)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
12.7 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ million)
- Data Table on US - Market size and forecast 2024-2029 ($ million)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
12.8 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ million)
- Data Table on Germany - Market size and forecast 2024-2029 ($ million)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
12.9 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ million)
- Data Table on Canada - Market size and forecast 2024-2029 ($ million)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
12.10 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ million)
- Data Table on China - Market size and forecast 2024-2029 ($ million)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
12.11 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ million)
- Data Table on UK - Market size and forecast 2024-2029 ($ million)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
12.12 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ million)
- Data Table on France - Market size and forecast 2024-2029 ($ million)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
12.13 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ million)
- Data Table on Japan - Market size and forecast 2024-2029 ($ million)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
12.14 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ million)
- Data Table on Italy - Market size and forecast 2024-2029 ($ million)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
12.15 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ million)
- Data Table on India - Market size and forecast 2024-2029 ($ million)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
12.16 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ million)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ million)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
12.17 Market opportunity By Geographical Landscape
- Market opportunity By Geographical Landscape ($ million)
- Data Tables on Market opportunity By Geographical Landscape ($ million)

13 Drivers, Challenges, and Opportunity/Restraints

13.1 Market drivers
13.2 Market challenges
13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
13.4 Market opportunities/restraints

14 Competitive Landscape

14.1 Overview
14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
14.3 Landscape disruption
- Overview on factors of disruption
14.4 Industry risks
- Impact of key risks on business

15 Competitive Analysis

15.1 Companies profiled
- Companies covered
15.2 Company ranking index
- Company ranking index
15.3 Market positioning of companies
- Matrix on companies position and classification
15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Product / Service
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- SWOT
15.5 Alcon Inc.
- Alcon Inc. - Overview
- Alcon Inc. - Business segments
- Alcon Inc. - Key news
- Alcon Inc. - Key offerings
- Alcon Inc. - Segment focus
- SWOT
15.6 Alimera Sciences Inc.
- Alimera Sciences Inc. - Overview
- Alimera Sciences Inc. - Product / Service
- Alimera Sciences Inc. - Key offerings
- SWOT
15.7 Bausch Health Companies Inc.
- Bausch Health Companies Inc. - Overview
- Bausch Health Companies Inc. - Business segments
- Bausch Health Companies Inc. - Key news
- Bausch Health Companies Inc. - Key offerings
- Bausch Health Companies Inc. - Segment focus
- SWOT
15.8 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key news
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
15.9 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
15.10 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
15.11 Johnson and Johnson Services Inc.
- Johnson and Johnson Services Inc. - Overview
- Johnson and Johnson Services Inc. - Business segments
- Johnson and Johnson Services Inc. - Key news
- Johnson and Johnson Services Inc. - Key offerings
- Johnson and Johnson Services Inc. - Segment focus
- SWOT
15.12 MeiraGTx Holdings Plc.
- MeiraGTx Holdings Plc. - Overview
- MeiraGTx Holdings Plc. - Product / Service
- MeiraGTx Holdings Plc. - Key offerings
- SWOT
15.13 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
15.14 Ocular Therapeutix Inc
- Ocular Therapeutix Inc - Overview
- Ocular Therapeutix Inc - Product / Service
- Ocular Therapeutix Inc - Key offerings
- SWOT
15.15 Oxurion N
- Oxurion N - Overview
- Oxurion N - Product / Service
- Oxurion N - Key offerings
- SWOT
15.16 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Product / Service
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- SWOT
15.17 Regeneron Pharmaceuticals Inc.
- Regeneron Pharmaceuticals Inc. - Overview
- Regeneron Pharmaceuticals Inc. - Product / Service
- Regeneron Pharmaceuticals Inc. - Key offerings
- SWOT
15.18 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT

16 Appendix

16.1 Scope of the report
16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
16.3 Currency conversion rates for US$
- Currency conversion rates for US$
16.4 Research methodology
- Research methodology
16.5 Data procurement
- Information sources
16.6 Data validation
- Data validation
16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
16.8 Data synthesis
- Data synthesis
16.9 360 degree market analysis
- 360 degree market analysis
16.10 List of abbreviations
- List of abbreviations